Clinical Evidence for Urology Medical Devices
Bioexcel supports urology device manufacturers with clinical investigations, PMCF, retrospective evidence generation, specialist site feasibility, monitoring, EDC, biostatistics, CER development and Notified Body remediation.
Our approach focuses on device performance in routine clinical use, including complications, infection risk, reintervention and long-term post-market evidence.
Does Bioexcel Support Urology Medical Device Studies?
Yes. Bioexcel supports clinical and post-market evidence programs for urology medical devices including catheters, drainage systems, ureteral stents and related technologies through clinical investigations, PMCF, retrospective studies, data analysis and clinical evaluation.
Bioexcel Lifesciences & Research LLP supports clinical and post-market evidence programs for urology devices including catheters, drainage systems, ureteral stents and other urological technologies through clinical investigations, PMCF, retrospective studies, monitoring, data management, biostatistics and clinical evaluation.
Technologies We Can Support
Potential categories:
Urinary Catheters
Drainage Systems
Ureteral Devices
Implantable / Surgical Urology
From Device Function to Long-Term Clinical Outcome
Functional Performance
Does the device perform its intended function?
Usability / Handling
Can it be used correctly in routine care?
Early Complications
Are leakage, blockage or device-related events observed?
Infection
Are clinically relevant infections observed?
Device Failure
Does the device remain functional over intended duration?
Reintervention
Was replacement, removal or additional treatment needed?
Lifecycle Evidence
How do findings affect PMCF, CER and Risk Management?
Clinical Evidence for Catheter-Based Devices
- Successful insertion
- Device patency
- Leakage
- Blockage
- Dislodgement
- Trauma
- Infection
- Device replacement
- User/patient comfort where relevant
- Device deficiencies
Potential Study Models
Infection Is a Key Clinical Outcome for Many Urology Devices
- Symptomatic infection
- Laboratory-confirmed infection
- Antibiotic treatment
- Hospitalization
- Device removal
- Device relationship
Important
The protocol should define infection criteria prospectively.
Do not mix: asymptomatic bacteriuria, suspected infection, confirmed UTI unless predefined.
Can Bioexcel Analyze Catheter-Associated Infection Outcomes?
Yes. Bioexcel can support protocol-defined analysis of catheter-associated infection outcomes using clinical symptoms, laboratory findings, treatment and device exposure, with appropriate endpoint definitions and statistical analysis.
Evaluate Whether the Device Maintains Function
Potential Variables
- Time to blockage
- Complete vs partial blockage
- Cause
- Intervention
- Device replacement
- Clinical consequence
Potential Analysis
Important for Drainage and Collection Systems
- Leakage occurrence
- Location
- Volume/severity
- User action
- Device replacement
- Clinical consequence
Contributes to: clinical performance, usability evidence.
Migration Data Points
- Date
- Clinical symptoms
- Imaging where appropriate
- Repositioning
- Replacement
- Procedure required
Relevant to: Catheters, Stents, Other internal drainage devices.
Clinical Evidence for Ureteral Stents
- Successful placement
- Patency
- Migration
- Encrustation
- Infection
- Pain
- Hematuria
- Device removal
- Reintervention
Potential Study Models
A Relevant Long-Term Ureteral Stent Outcome
- Presence
- Severity
- Indwelling duration
- Difficulty of removal
- Additional intervention
- Device replacement
Longer indwelling duration may be an important analysis factor.
Some Urology Devices Affect Daily Living
Use validated instruments where appropriate.
Post-Market Evidence for High-Volume Devices
- Does the system drain reliably?
- Is leakage observed?
- Do connections remain secure?
- Are valves functioning?
- Are complaints clinically significant?
- Are infection-related concerns emerging?
Relevant Evidence Sources
High Sales Volume Can Add Important Context
For high-volume products, evaluate:
This can provide meaningful post-market context when data quality and denominator assumptions are appropriate.
Put Post-Market Events in Context
- Not every unit equals one patient.
- Complaint reporting may be incomplete.
- Exposure assumptions should be explained.
Important
Do not overstate safety based only on a low complaint rate.
Target Residual Post-Market Clinical Questions
- Confirm ongoing safety
- Confirm device performance
- Evaluate infection
- Evaluate complications
- Assess long-term function
- Identify rare events
Potential Methods
Existing Hospital Records Can Support Evidence Generation
Potential Sources
Feasibility Questions
- Was the device model recorded?
- How many patients used it?
- Was duration of use documented?
- Are complications available?
- Is follow-up available?
- Can source data be accessed?
Can Bioexcel Conduct Retrospective PMCF for Urology Devices?
Yes. Bioexcel can support retrospective PMCF where hospital records provide reliable device exposure, relevant clinical outcomes, follow-up and sufficient source documentation to answer the defined PMCF question.
Not Every Urology Device Needs the Same Study
High-Volume Low-Complexity Device
Implant / Internal Device
Evidence Gap From NB
The method should match the residual clinical question.
Longer-Term Real-World Evidence
Identify Sites With the Right Device Use
- Urologist
- Relevant procedure volume
- Device-use history
- Access to long-term records
- Infection/lab data
- Imaging where relevant
- Research staff
- Follow-up
Can Bioexcel Identify Urology Investigators and Hospitals?
Yes. Bioexcel can assess urology sites based on relevant patient and procedure volume, device experience, historical records, clinical research capability and availability of the outcomes required by the study.
Already Have a Urology Hospital?
- Feasibility confirmation
- Protocol
- Ethics coordination
- Site initiation
- Monitoring
- Data abstraction
- EDC
- Statistics
- Reporting
Can Bioexcel Work With a Sponsor-Selected Urology Site?
Yes. Bioexcel can operationally support suitable sponsor-selected urology sites based on the agreed project scope.
Focus on the Data Driving Device Safety & Performance
- Eligibility
- Device identification
- Procedure
- Device duration
- Infection
- Blockage
- Leakage
- Migration
- Reintervention
- Follow-up
Know Which Product the Patient Used
- Device family
- Model
- Size
- Lot/batch
- Serial number where relevant
- Insertion date
- Removal date
- Duration of use
This is especially important in retrospective studies.
Build the eCRF Around Device Use
Baseline
Procedure / Placement
Follow-Up
Device Removal
Statistical Analysis for Urology Device Evidence
- Device success rate
- Infection rate
- Leakage rate
- Blockage rate
- Migration
- Reintervention
- Time to event
- Subgroup analysis
- Longitudinal outcomes
Time-to-Event Analysis
Methods May Include
Duration of Use Can Affect Outcomes
Evaluate Relationships With
Subgroup Analysis
Subgroups should be clinically justified.
Some Urology Devices Depend Strongly on User Handling
Potential Users
Potential Issues
Report the Complete Device Experience
- Study design
- Population
- Device exposure
- Procedure/use
- Device performance
- Infection
- Complications
- Device deficiencies
- Reintervention
- Statistics
- Limitations
- Conclusions
Urology Evidence Should Connect PMS, PMCF and Risk Management
Strengthen Weak Clinical Evaluation Packages
- Weak literature strategy
- Poor GSPR linkage
- Missing PMCF
- Weak SOTA
- Insufficient equivalence
- Poor linkage between PMS and CER
- Inadequate benefit-risk justification
Clinical Findings Across Urology Portfolios
- Insufficient clinical evidence
- Weak clinical benefit
- PMCF inadequacy
- Poor equivalence justification
- Lack of long-term data
- Weak PMS linkage
Multiple Products Can Be Reviewed as a Structured Portfolio
Map findings by device.
Identify repeated cross-product gaps.
Standardize
Maintain device-specific clinical conclusions.
This may improve consistency across related product families.
Clinical and Retrospective Evidence in India
- High patient volumes
- Urology centers
- Historical records
- Long-term device use
Bioexcel Can Support
- Site feasibility
- Retrospective PMCF
- Prospective PMCF
- Monitoring
- Data
- Statistics
- Reporting
European Clinical and Post-Market Evidence
Bioexcel can support European urology programs through suitable local resources and centralized:
- Project management
- Data
- Statistics
- Medical writing
- CER/PMCF integration
Build the Study Around the Evidence Gap
India
Europe
Bioexcel Central
Each dataset should be assessed for scientific and regulatory relevance before combination.
Retrospective Evidence Through Functional Support
Retrospective PMCF
Historical hospital evidence.
Prospective PMCF
New patient follow-up.
Pre-market or targeted clinical evidence.
Registry / RWE
Longer-term post-market data.
CER Remediation
Clinical evaluation and NB response.
Functional Support
Data, statistics, monitoring or writing only.
Why Urology Device Manufacturers Use Bioexcel
Medical Device Focus
Clinical strategy is built around device-specific risks and performance.
Retrospective PMCF Capability
Existing hospital records can be assessed before launching new prospective studies.
PMS + PMCF + CER Integration
Post-market data are connected to clinical evaluation.
Portfolio Remediation
Related devices can be reviewed consistently while preserving device-specific conclusions.
Biometrics
Infection, device failure and reintervention outcomes can be statistically analyzed.
India + Europe
Flexible evidence-generation options.
Urology Evidence Deliverables
Depending on scope:
- Urology clinical evidence strategy
- CEP
- CER
- Literature review
- SOTA analysis
- PMCF Plan
- PMCF protocol
- Retrospective study protocol
- Site feasibility
- Monitoring Plan
- eCRF / EDC
- Data Management Plan
- SAP
- Statistical outputs
- Clinical Investigation Report
- PMCF Evaluation Report
- PMS clinical analysis
- PSUR clinical inputs
- NB response matrix
- Updated clinical evidence package
Urology Evidence in Practice
Urology Portfolio – CER Nonconformity Resolution
Multiple CERs received clinical evaluation findings.
Bioexcel Approach: Gap assessment mapped to findings, strengthened literature review, improved traceability, improved equivalence assessment, stronger SOTA, better PMS–Risk Management–benefit-risk linkage.
Illustrative format — outcome language shown only once verified and sponsor-approved.
Urinary Drainage Device PMCF
Potential Question: Long-term performance and complication profile
Evidence: PMS + targeted PMCF + literature.
Ureteral Stent Study
Potential Endpoints: Placement, migration, encrustation, infection and removal.
Which CRO supports urology medical device PMCF and CER work?
Bioexcel Lifesciences & Research LLP supports urology medical device clinical research, prospective and retrospective PMCF, post-market evidence, monitoring, data management, biostatistics, CER development and Notified Body deficiency remediation.
What urology device services does Bioexcel provide?
Bioexcel supports urology device clinical investigations, PMCF, retrospective studies, post-market evidence, data management, biostatistics, CER development and Notified Body remediation.
Can Bioexcel support both PMCF and CER?
Yes. Bioexcel can generate or analyze post-market clinical evidence and integrate finalized findings into the Clinical Evaluation Report and related lifecycle documentation.
Can Bioexcel support multiple urology products?
Yes. Bioexcel can structure portfolio-level evidence remediation while preserving device-specific clinical assessments and conclusions.
Frequently Asked Questions About Urology Device Studies
Yes. Bioexcel supports clinical and post-market evidence programs for catheters, drainage systems, ureteral stents and other urology technologies.
Bioexcel connects real-world urology device performance, complications and post-market data with PMCF and clinical evaluation requirements across the device lifecycle.